0000899243-23-018361.txt : 20230823 0000899243-23-018361.hdr.sgml : 20230823 20230823211528 ACCESSION NUMBER: 0000899243-23-018361 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230823 FILED AS OF DATE: 20230823 DATE AS OF CHANGE: 20230823 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moran Kyle CENTRAL INDEX KEY: 0001657765 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37627 FILM NUMBER: 231198758 MAIL ADDRESS: STREET 1: C/O WAVE LIFE SCIENCES LTD. STREET 2: 733 CONCORD AVE. CITY: CAMBRIDGE STATE: MA ZIP: 02138 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Wave Life Sciences Ltd. CENTRAL INDEX KEY: 0001631574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: U0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 STRAITS VIEW STREET 2: #12-00, MARINA ONE EAST TOWER CITY: SINGAPORE STATE: U0 ZIP: 018936 BUSINESS PHONE: 617-949-2900 MAIL ADDRESS: STREET 1: 733 CONCORD AVENUE CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: WAVE Life Sciences Ltd. DATE OF NAME CHANGE: 20170516 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences Ltd. DATE OF NAME CHANGE: 20151106 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences LTD. DATE OF NAME CHANGE: 20151106 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-08-23 0 0001631574 Wave Life Sciences Ltd. WVE 0001657765 Moran Kyle C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE. CAMBRIDGE MA 02138 0 1 0 0 Chief Financial Officer 1 Ordinary Shares 2023-08-23 4 S 0 37062 4.752 D 46120 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 10, 2023. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.75 to $4.76 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Includes 3,431 ordinary shares acquired on July 14, 2023, under the issuer's 2019 Employee Share Purchase Plan. /s/ Kyle Moran 2023-08-23